A clinical trial of clobetasol propionate in Filipino vitiligo patients.
Twenty-five patients with vitiligo lesions were treated intermittently with topical clobetasol propionate cream over a period of eight months or less. After six months of treatment, 22 of the 25 patients showed at least 90% repigmentation. The age of the patient, duration and anatomic site of the lesion, and presence or absence of achromotrichia proved to be significant prognosticators of the response to therapy. The results of the study suggest a possible simplified therapeutic option for this skin disorder.